Activity and safety of temozolomide in advanced adrenocortical carcinoma patients

in European Journal of Endocrinology
View More View Less
  • 1 Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy
  • 2 Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
  • 3 Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy
  • 4 Department of Oncology, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy
  • 5 Department of Medical Oncology, AOU di Modena, Modena, Italy
  • 6 Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy

Correspondence should be addressed to A Berruti; Email: alfredo.berruti@gmail.com

*(D Cosentini and G Badalamenti contributed equally to this work)

Restricted access

Objective

Temozolomide has shown a significant anti-proliferative activity on adrenocortical cancer (ACC) cells in vitro.

Design

On the basis of these results the drug was prescribed as second/third line in advanced metastatic ACC patients in four referral centers in Italy.

Methods

We retrospectively collected anagraphic, clinical and pathological data of patients with advanced ACC with disease progression to standard chemotherapy plus mitotane who were treated with temozolomide at the dose of 200 mg/m2/die given for 5 consecutive days every 28 days. The primary endpoint was the disease control rate, defined as objective response or disease stabilization after 3 months. Secondary endpoints were overall survival (OS), progression-free survival (PFS) and drug safety.

Results

Twenty-eight patients have been included in the study. Ten patients (35.8%, 95% CI: 17.8–53.8) obtained a disease control from temozolomide treatment. In particular, 1 patient had a complete response, 5 patients a partial response and 4 patients stable disease. Median PFS was 3.5 months and median OS was 7.2 months. Disease response was more frequently observed in patients with methylation of O6-methylguanine-DNA methyltransferase (MGMT) gene. Temozolomide therapy was well tolerated and most toxicities were limited to grade G1–2 according to WHO criteria.

Conclusion

Temozolomide was found active in the management of advanced ACC patients. The disease control rate obtained, however, was short-lived and the prognosis of treated patients was poor.

 

     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 953 953 81
Full Text Views 120 120 3
PDF Downloads 98 98 3
  • 1

    Terzolo M, Daffara F, Ardito A, Zaggia B, Basile V, Ferrari L, Berruti A. Management of adrenal cancer: a 2013 update. Journal of Endocrinological Investigation 2014 207217. (https://doi.org/10.1007/s40618-013-0049-2)

    • Search Google Scholar
    • Export Citation
  • 2

    Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger RR, Haak HR, Mihai R, Assie G, Terzolo M. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. European Journal of Endocrinology 2018 G1G46. (https://doi.org/10.1530/EJE-18-0608)

    • Search Google Scholar
    • Export Citation
  • 3

    Berruti A, Baudin E, Gelderblom H, Haak HR, Porpiglia F, Fassnacht M, Pentheroudakis G & ESMO Guidelines Working Group. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2012 (Supplement 7) vii131vii138. (https://doi.org/10.1093/annonc/mds231)

    • Search Google Scholar
    • Export Citation
  • 4

    Berruti A, Grisanti S, Pulzer A, Claps M, Daffara F, Loli P, Mannelli M, Boscaro M, Arvat E & Tiberio G Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2017 13581365. (https://doi.org/10.1210/jc.2016-2894)

    • Search Google Scholar
    • Export Citation
  • 5

    Terzolo M, Baudin AE, Ardito A, Kroiss M, Leboulleux S, Daffara F, Perotti P, Feelders RA, deVries JH & Zaggia B Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. European Journal of Endocrinology 2013 263270. (https://doi.org/10.1530/EJE-13-0242)

    • Search Google Scholar
    • Export Citation
  • 6

    Berruti A, Fassnacht M, Haak H, Else T, Baudin E, Sperone P, Kroiss M, Kerkhofs T, Williams AR & Ardito A Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. European Urology 2014 832838. (https://doi.org/10.1016/j.eururo.2013.11.006)

    • Search Google Scholar
    • Export Citation
  • 7

    Berruti A, Terzolo M, Sperone P, Pia A, Della Casa S, Gross DJ, Carnaghi C, Casali P, Porpiglia F & Mantero F Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocrine-Related Cancer 2005 657666. (https://doi.org/10.1677/erc.1.01025)

    • Search Google Scholar
    • Export Citation
  • 8

    Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A & Jarzab B Combination chemotherapy in advanced adrenocortical carcinoma. New England Journal of Medicine 2012 21892197. (https://doi.org/10.1056/NEJMoa1200966)

    • Search Google Scholar
    • Export Citation
  • 9

    Megerle F, Kroiss M, Hahner S, Fassnacht M. Advanced adrenocortical carcinoma – what to do when first-line therapy fails? Experimental and Clinical Endocrinology and Diabetes 2019 109116. (https://doi.org/10.1055/a-0715-1946)

    • Search Google Scholar
    • Export Citation
  • 10

    Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, Santini D, Vincenzi B, Badalamenti G & Intrivici C Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocrine-Related Cancer 2010 445453. (https://doi.org/10.1677/ERC-09-0281)

    • Search Google Scholar
    • Export Citation
  • 11

    Henning JEK, Deutschbein T, Altieri B, Steinhauer S, Kircher S, Sbiera S, Wild V, Schlötelburg W, Kroiss M & Perotti P Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicenter study of efficacy and predictive factors. Journal of Clinical Endocrinology and Metabolism 2017 43234332. (https://doi.org/10.1210/jc.2017-01624)

    • Search Google Scholar
    • Export Citation
  • 12

    Konda B, Kirschner LS. Novel targeted therapies in adrenocortical carcinoma. Current Opinion in Endocrinology, Diabetes, and Obesity 2016 233241. (https://doi.org/10.1097/MED.0000000000000247)

    • Search Google Scholar
    • Export Citation
  • 13

    Le Tourneau C, Zarwan C, Hoimes C, Wong DJ, Bauer S, Wermke M, Grote HJ, von Heydebreck A, Chin K, Gulley J. Avelumab in patients with metastatic adrenocortical carcinoma (mACC): results from the JAVELIN solid tumor trial. Annals of Oncology 2017 (Supplement 5) mdx371.067. (https://doi.org/10.1186/s40425-018-0424-9)

    • Search Google Scholar
    • Export Citation
  • 14

    Cosentini D, Grisanti S, Dalla Volta A, Laganà M, Fiorentini C, Perotti P, Sigala S, Berruti A. Immunotherapy failure in adrenocortical cancer: where next? Endocrine Connections 2018 7 E5E8. (https://doi.org/10.1530/EC-18-0398)

    • Search Google Scholar
    • Export Citation
  • 15

    Ma W, Li N, An Y, Zhou C, Bo C, Zhang G. Effects of temozolomide and radiotherapy on brain metastatic tumor: a systematic review and meta-analysis. World Neurosurgery 2016 197205. (https://doi.org/10.1016/j.wneu.2016.04.011)

    • Search Google Scholar
    • Export Citation
  • 16

    Koumarianou A, Kaltsas G, Kulke MH, Oberg K, Strosberg JR, Spada F, Galdy S, Barberis M, Fumagalli C & Berruti A Temozolomide in advanced neuroendocrine neoplasms: pharmacological and clinical aspects. Neuroendocrinology 2015 274288. (https://doi.org/10.1159/000430816)

    • Search Google Scholar
    • Export Citation
  • 17

    Hadoux J, Favier J, Scoazec JY, Leboulleux S, Al Ghuzlan A, Caramella C, Déandreis D, Borget I, Loriot C & Chougnet C SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. International Journal of Cancer 2014 27112720. (https://doi.org/10.1002/ijc.28913)

    • Search Google Scholar
    • Export Citation
  • 18

    Creemers SG, van Koetsveld PM, van den Dungen ES, Korpershoek E, van Kemenade FJ, Franssen GJ, de Herder WW, Feelders RA, Hofland LJ. Inhibition of human adrenocortical cancer cell growth by temozolomide in vitro and the role of the MGMT gene. Journal of Clinical Endocrinology and Metabolism 2016 45744584. Erratum in: Journal of Clinical Endocrinology and Metabolism 2018 31153118. (https://doi.org/10.1210/jc.2016-2768)

    • Search Google Scholar
    • Export Citation
  • 19

    Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. New England Journal of Medicine 2000 13501354. (https://doi.org/10.1056/NEJM200011093431901) Erratum in: New England Journal of Medicine 2000 1740.

    • Search Google Scholar
    • Export Citation
  • 20

    Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clinical Cancer Research 2004 18711874. (https://doi.org/10.1158/1078-0432.CCR-03-0384)

    • Search Google Scholar
    • Export Citation
  • 21

    Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W & Mariani L MGMT gene silencing and benefit from temozolomide in glioblastoma. New England Journal of Medicine 2005 9971003. (https://doi.org/10.1056/NEJMoa043331)

    • Search Google Scholar
    • Export Citation
  • 22

    Baudin E & Endocrine Tumor Board of Gustave Roussy. Adrenocortical carcinoma. Endocrinology and Metabolism Clinics of North America 2015 411434. (https://doi.org/10.1016/j.ecl.2015.03.001) Review Erratum in: Endocrinology and Metabolism Clinics of North America 2015 xix

    • Search Google Scholar
    • Export Citation
  • 23

    Ferrero A, Sperone P, Ardito A, Rossi G, Del Buono S, Priola AM, Bracarda S, Taberna E, Terzolo M, Berruti A. Metronomic chemotherapy may be active in heavily pre-treated patients with metastatic adreno-cortical carcinoma. Journal of Endocrinological Investigation 2013 148152. (https://doi.org/10.3275/8334)

    • Search Google Scholar
    • Export Citation
  • 24

    Khan TS, Imam H, Juhlin C, Skogseid B, Gröndal S, Tibblin S, Wilander E, Oberg K, Eriksson B. Streptozocin and o,p′DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Annals of Oncology 2000 12811287. (https://doi.org/10.1023/a:1008377915129)

    • Search Google Scholar
    • Export Citation
  • 25

    Bae SH, Park MJ, Lee MM, Kim TM, Lee SH, Cho SY, Kim YH, Kim YJ, Park CK, Kim CY. Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea. Journal of Korean Medical Science 2014 980984. (https://doi.org/10.3346/jkms.2014.29.7.980)

    • Search Google Scholar
    • Export Citation
  • 26

    Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. Journal of Clinical Oncology 2008 39133915. (https://doi.org/10.1200/JCO.2008.16.1000)

    • Search Google Scholar
    • Export Citation